The timing of hormonal treatment for prostate cancer.
This article reviews publications investigating the optimal timing of androgen ablative therapy for prostate cancer. We regard with some concern retrospective series, the use of endpoints other than overall survival, the presentation of actuarial and not actual survival, and the omission of appropriate controls. Treatment of minimal residual disease and other clinical scenarios are explored.
Eichel
L
L
Department of Urology, University of Rochester School of Medicine, New York 14642, USA.
Messing
E
E
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D018365:Neoplasm, Residual; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D015203:Reproducibility of Results; D016019:Survival Analysis; D013997:Time Factors
D000726:Androgen Antagonists